Citations with the tag: DOPA

Results 1 - 50

  • Is levodopa a risk factor for the development of malignant melanoma?
     // Age & Ageing; Jan97 Supplement, Vol. 26, p16 

    Presents an abstract of the study `Is Levodopa a Risk Factor for the Development of Malignant Melanoma?,' by P. Medcalf and H.J. Sagar, presented during the communications to the autumn meeting of the British Geriatrics Society on October 3-4, 1996 in London, England.

  • 3,4-dihydroxyphenylalanine.
     // Taber's Cyclopedic Medical Dictionary (2009); 2009, Issue 21, p654 

    A definition of the term "3,4-dihydroxyphenylalanine" which refers to L-phenylalanine is presented.

  • L-dopa.
     // Taber's Cyclopedic Medical Dictionary (2009); 2009, Issue 21, p1309 

    A definition of the acronym "L-dopa," which refers to L-3,4-dihydroxyphenylalanine, is presented.

  • Levodopa/carbidopa.
     // Reactions Weekly; 10/23/2010, Issue 1324, p25 

    The article describes the cases of four women and three men aged 57 to 83 years who developed neuropathies while receiving continuous infusions of levodopa with carbidopa.

  • The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Psychopharmacology; May2009, Vol. 204 Issue 1, p185 

    A correction is presented to the article "The Sigma-1 Antagonist BMY-14802 Inhibits L-Dopa-Induced Abnormal Involuntary Movements by a WAY-100635-Sensitive Mechanism" by Melanie A. Paquette, Katherine Foley, Elizabeth G. Brudney, Charles K. Meshul, Steven W. Johnson and S. Paul Berger.

  • Levodopa/carbidopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 3/12/2011, Issue 1342, p22 

    The article describes the case of a 45-year-old man with Parkinson's disease who developed painful off-period dystonia while undergoing levodopa/carbidopa treatment.

  • Levodopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 6/9/2012, Issue 1405, p23 

    The article describes two cases, involving a 7-year-old boy and a 22-year-old man who developed fluctuating hyperprolactinaemia during treatment with levodopa for severe dihydropteridine reductase (DHPR) deficiency, published in the April 2012 issue of "Molecular Genetics and Metabolism."

  • Levodopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 2/27/2010, Issue 1290, p31 

    The article describes the case of a middle-aged man who developed diphasic chorea during levodopa therapy for multiple system atrophy and parkinsonism.

  • Levodopa/carbidopa/sildenafil interaction.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 2/27/2010, Issue 1290, p32 

    The article describes the case of a 56-year-old man who was hospitalised with choreoathetosis and an erection after taking sildenafil which interacted with levodopa and carbidopa for Parkinson's disease.

  • Levodopa/carbidopa/ropinirole/rotigotine.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 11/19/2011, Issue 1378, p23 

    The article describes a case of gambling addiction that developed in a 62-year-old man during treatment with levodopa/carbidopa, ropinirole and rotigotine for restless leg syndrome.

  • Levodopa/carbidopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 8/25/2012, Issue 1416, p28 

    The article describes the cases of two elderly men with Parkinson's disease (PD) who developed knotting of their percutaneous endoscopic jejunostomy (PEJ) feeding tubes during treatment with levodopa/carbidopa.

  • Levodopa/benserazide.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 5/5/2012, Issue 1400, p27 

    The article describes the case of a patient with Parkinson's disease and progressive supranuclear palsy who developed unilateral gynecomastia after receiving treatment with levodopa/benserazide.

  • Levodopa/benserazide/ropinirole.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 5/5/2012, Issue 1400, p27 

    The article describes the case of a patient who experienced an augmentation of restless legs syndrome during treatment with levodopa/benserazide and ropinirole.

  • Levodopa/risperidone/tetrabenazine.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 5/5/2012, Issue 1400, p27 

    The article describes the case of a patient with brain-lung-thyroid disease who developed falls with risperidone treatment, instability with tetrabenazine and sedation from levodopa.

  • Levodopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 9/18/2010, Issue 1319, p30 

    The article describes the case of a 35-year-old man, diagnosed with Parkinson's therapy, who presented with painful off-period dystonia, levodopa-related motor fluctuations and moderate peak-dose dyskinesia, referencing a study published in the August 2010 issue of the journal "Parkinsonism and...

  • Levodopa withdrawal.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 3/19/2011, Issue 1343, p24 

    The article describes the case of an 84-year-old man with chronic schizophrenia who developed neuroleptic malignant-like syndrome following levodopa withdrawal.

  • Droxidopa/levodopa/carbidopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 7/28/2012, Issue 1412, p19 

    The article describes the case of a man in his late 50s who developed dopamine dysregulation syndrome while under levodopa/carbidopa and droxidopa treatment regimen.

  • Levodopa/carbidopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 8/31/2013, Issue 1467, p24 

    The article presents the case of a 69-year-old man who developed mydriasis while receiving carbidopa/levodopa.

  • Levodopa/carbidopa.
    Paquette, Melanie; Foley, Katherine; Brudney, Elizabeth; Meshul, Charles; Johnson, Steven; Berger, S. // Reactions Weekly; 8/31/2013, Issue 1467, p24 

    The article presents the case of an 84-year-old woman who developed a worsening of migraines during treatment with levodopa/carbidopa.

  • Beneficial Effects of Combined L-dopa and Central Anticholinergic in a Patient With Severe Drug-Induced Parkinsonism and Tardive Dystonia.
    Looper, Karl J. // Canadian Journal of Psychiatry; Aug98, Vol. 43 Issue 6, p646 

    A letter to the editor is presented discussing the beneficial effects of combined L-dopa and central anticholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia.

  • Acute effects of L-dopa on event-related desynchronization in Parkinson's disease.
    Magnani, G.; Cursi, M.; Leocani, L.; Volont�, M. A.; Comi, G. // Neurological Sciences; Sep2002, Vol. 23 Issue 3, p91 

    We tested whether dispersible L-dopa has acure effects on event-related desynchronization (ERD) of the mu rhythm in patients with idiopathic Parkinson's disease (IPD). ERD to voluntary movement is delayed in akinetic IPD patients and improves after chronic L-dopa treatment. We evaluated ERD to...

  • Psychophysiological approach in Parkinson's disease: L-dopa effects on preprogramming and control activity.
    Fattapposta, F.; Pierelli, F.; My, F.; Mostarda, M.; Del Monte, S.; Parisi, L.; Serrao, M.; Locuratolo, N.; Amabile, G. // Neurological Sciences; Sep2002 Supplement 2, Vol. 23, pS73 

    To investigate whether preprogramming (Bereitschaftspotential, BP) and control activity (skilled performance positivity, SPP) in a complex task are sensitive to L-dopa, movement related potentials (MRPs) were recorded in 12 non-demented Parkinson's disease (PD) patients before and after acute...

  • Yet another drug induces Parkinson's symptoms.
    Fattapposta, F.; Pierelli, F.; My, F.; Mostarda, M.; Del Monte, S.; Parisi, L.; Serrao, M.; Locuratolo, N.; Amabile, G. // Brown University Long-Term Care Quality Letter; 1/15/96, Vol. 8 Issue 1, p7 

    Reports that a study by the National Institute on Aging shows that medication containing L-dopa may be used by older people taking metoclopramide (Reglan) in the therapy for Parkinson's disease. First sign of evidence linking metoclopramide with parkinsonian symptoms. INSET: Editor's note, by...

  • The levodopa test in Parkinson's disease.
    D'Costa, D.F.; Sheehan, L.J. // Age & Ageing; May95, Vol. 24 Issue 3, p210 

    Assesses whether a single levodopa challenge could predict dopa responsiveness in patients with Parkinson's disease. Patients showing improvement with treatment; Condition of patients with negative results; Confirmation of the diagnosis of Parkinson's disease.

  • Drugs that induce changes in urine color.
    DiPalma, Joseph R. // RN; Jan77, Vol. 40 Issue 1, p34 

    Presents a lists of known instances of drug-induced changes in urine color. Urine color change due to amitriptyline; Impact of levodopa on urine color; Effect of metronidazole on urine color.

  • SHORT REPORTS.
    Briet, E.; Vismans, F.J.; van Voorthuisen, A.E.; Oswald, Ian; Adam, Kirstine; Barrison, I.G.; Viola, L.; Murray-Lyon, Iain M.; Jenkins, J.; Sainsbury, P.; van de Wiel, A.; Flinterman, J.; Kerckhaert, J.A.M.; Boeff, J.A.Du; Imhof, J.W.; Bydder, G.M.; Chapman, R.W.G.; Findley, L.J. // British Medical Journal; 10/18/1980, Vol. 281 Issue 6247, p1039 

    Reports developments related to medicine. Effects of Benzodiazepine on weight; Preference on the use of bupivacaine on intravenous regional analgesia; Action of levodopa on the suppression of tremor.

  • Levodopa and the Progression of Parkinson's Disease.
    Walton-Hadlock, Janice L. // New England Journal of Medicine; 3/31/2005, Vol. 352 Issue 13, p1386 

    A letter to the editor is presented in response to a study on levodopa and the progression of Parkinson's Disease by the Parkinson Study Group in the December 9, 2004 issue.

  • Parkinson's disease.
    Grayson, Michelle // Nature; 8/26/2010 Supplement, Vol. 466 Issue 7310, pS1 

    An introduction to the journal is presented in which the editor discusses an article on levodopa as a symptomatic drug available for treating Parkinson, on animal models for novel treatment of Parkinson's disease, and on the appropriateness of disease-modifying therapies in patient's testing.

  • Novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer.
    Lozano, Ramon Herreros; Jofre, Irene Serrat // Palliative Medicine; Oct2002, Vol. 16 Issue 6, p548 

    Focuses on the novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer. Alleged improvement in anorexia patients.

  • Early Treatment of Parkinson's Disease with Cabergoline Delays the Onset of Motor Complications: Results of a Double-Blind Levodopa Controlled Trial.
    Rinne, U.K.; Bracco, F.; Chouza, C.; Dupont, E.; Gershanik, O.; Masso, J.F.M.; Montastruc, J.L.; Marsden, C.D. // Drugs; Jan1998 Supplement 1, Vol. 55 Issue 1, p23 

    This multicentre randomised double-blind 3- to 5-year trial was designed to assess whether initial therapy with cabergoline alone or in combination with levodopa prevents or delays the occurrence of long term motor complications in patients with early Parkinson's disease. Patients eligible for...

  • Clinical Experience with Cabergoline in Patients with Advanced Parkinson's Disease Treated with Levodopa.
    Marsden, C.D. // Drugs; Jan1998 Supplement 1, Vol. 55 Issue 1, p17 

    The clinical efficacy of the long-acting dopamine agonist cabergoline as an adjunct to levodopa has been investigated in controlled and uncontrolled studies in >1500 patients with advanced Parkinson's disease and motor complications. Four of these studies (including 2 comparisons with placebo...

  • Pharmacodynamic and Pharmacokinetic Features of Cabergoline: Rationale for Use in Parkinson's Disease.
    Fariello, R.G. // Drugs; Jan1998 Supplement 1, Vol. 55 Issue 1, p10 

    The appearance of late motor complications is the major drawback of long term levodopa therapy in patients with Parkinson's disease. Although disease progression may be a factor in the aetiology of these complications, unfavourable properties of levodopa may promote their development. These...

  • The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease.
    Chase, T.N. // Drugs; Jan1998 Supplement 1, Vol. 55 Issue 1, p1 

    Levodopa continues to be the most effective agent for the symptomatic treatment of Parkinson's disease. No other drug matches its ability to suppress parkinsonian symptoms, especially in patients with advanced disease. But over time, initial benefits begin to wane, not so much because of a...

  • Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States.
    Palmer, C.S.; Nuijten, M.J.C.; Schmier, J.K.; Subedi, P.; Snyder, E.H. // PharmacoEconomics; 2002, Vol. 20 Issue 9, p617 

    Objective: To determine the cost effectiveness of adjunctive therapy with entacapone versus standard treatment (levodopa) without entacapone for patients in the US with Parkinson's disease (PD) who experience ‘off-time’ (re-emergence of the symptoms of PD) while receiving levodopa....

  • dopa, DOPA.
    Palmer, C.S.; Nuijten, M.J.C.; Schmier, J.K.; Subedi, P.; Snyder, E.H. // Taber's Cyclopedic Medical Dictionary (2009); 2009, Issue 21, p682 

    An encyclopedia entry for the term "dopa" or "DOPA," which refers to the chemical substance 3,4-dihydroxyphenylalanine, is presented.

  • dopa-oxidase.
    Palmer, C.S.; Nuijten, M.J.C.; Schmier, J.K.; Subedi, P.; Snyder, E.H. // Taber's Cyclopedic Medical Dictionary (2009); 2009, Issue 21, p682 

    A definition of the term "dopa-oxidase" which refers to an enzyme that converts dopa into melanin is presented.

  • Antiparkinsonians.
    Palmer, C.S.; Nuijten, M.J.C.; Schmier, J.K.; Subedi, P.; Snyder, E.H. // Reactions Weekly; 9/4/2010, Issue 1317, p13 

    The article describes the case of a 65-year-old woman who had a spontaneous coronary artery dissection during treatment with levodopa, carbidopa, trihexyphenidyl, rasagline, and pramipexole for Parkinson's disease.

  • Neuropathy Pt.
    Sullivan, Tip; Udell, Elliot; Goldstein, Steven H. // Podiatry Management; Sep2008, Vol. 27 Issue 7, p22 

    The article provides an answer to a question of whether anyone routinely use Sinemet carbidopa/levodopa for the treatment of peripheral neuropathy of diabetes mellitus (DM).

  • Levodopa.
    Sullivan, Tip; Udell, Elliot; Goldstein, Steven H. // Reactions Weekly; 10/2/2010, Issue 1321, p23 

    The article describes the case of a 72-year-old woman who developed belly dancer's dyskinesias while under levodopa treatment regimen.

  • Levodopa.
    Sullivan, Tip; Udell, Elliot; Goldstein, Steven H. // Reactions Weekly; 8/18/2012, Issue 1415, p31 

    The article describes the case of a girl who developed dyskinesias while being treated with levodopa.

  • Levodopa/carbidopa.
    Sullivan, Tip; Udell, Elliot; Goldstein, Steven H. // Reactions Weekly; 8/18/2012, Issue 1415, p31 

    The article describes the case of a 45-year-old woman who developed dyskinesias while being treated with levodopa and carbidopa.

  • Effects of levodopa on upper limb mobility and gait in Parkinson's disease.
    Vokaer M; Azar N Abou; De Beyl D Zegers // Journal of Neurology, Neurosurgery & Psychiatry; Sep2003, Vol. 74 Issue 9, p1304 

    BACKGROUND: Most clinicians rely on clinical scales such as the unified Parkinson's disease rating scale (UDPRS) for evaluating parkinsonian patients and assessing their response to levodopa. Gait analysis is not commonly used, probably because of the equipment required and the time needed. Few...

  • Plasma 3, 4-Dihydroxyphenylalanine (Dopa) and Catecholamines in Neuroblastoma or Pheochromocytoma.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Annals of Internal Medicine; Dec86, Vol. 105 Issue 6, p887 

    Studies the plasma 3, 4-dihydroxyphenylalanine or Dopa and catecholamines in neuroblastoma or pheochromocytoma. Clinical characteristics of neuroblastomas and pheochromocytoma; Methodology of the study.

  • Levodopa.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Reactions Weekly; 9/15/2012, Issue 1419, p33 

    The article describes the case of a 21-year-old man who developed dyskinesias, leading to rhabdomyolysis, during treatment with levodopa.

  • Levodopa/carbidopa.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Reactions Weekly; 3/20/2010, Issue 1293, p33 

    The article describes the case of a 48-year-old man with Parkinson's disease who developed pain and dyskinesia while receiving levodopa/carbidopa.

  • Cabergoline/levodopa.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Reactions Weekly; 12/3/2011, Issue 1380, p11 

    The article describes the case of a 68-year-old man who developed hallucinations and delusions while being treated with cabergoline and levodopa for Parkinson's disease.

  • Levodopa/carbidopa/nitrous oxide.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Reactions Weekly; 3/27/2010, Issue 1294, p24 

    The article describes the case of a 74-year-old woman with Parkinson's disease who developed reversible encephalopathy and axonal neuropathy during treatment with levodopa/carbidopa.

  • Levodopa/pramipexole/selegiline.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Reactions Weekly; 3/27/2010, Issue 1294, p24 

    The article describes the case of a 63-year-old man with Parkinson's disease who developed pathological gambling when he overused pramipexole, selegiline and levodopa.

  • Levodopa.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // Reactions Weekly; May2014, Vol. 1503 Issue 1, p26 

    An abstract of the article "Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients," by M. Politis and colleagues is presented.

  • Personal View.
    Goldstein, David S.; Stull, Robin; Eisenhoffer, Graeme; Sisson, James C.; Weder, Alan; Averbuch, Steve D.; Keiser., Harry R. // British Medical Journal (Clinical Research Edition); 8/27/1983, Vol. 287 Issue 6392, p607 

    Relates the struggle of the author with Parkinson's disease in Great Britain. Feeling of depression; Treatment with levodopa and Sinemet Plus; Identification of affected parts.

Next 50 Results
Share

Other Topics